NeoGenomics (NEO)
(Delayed Data from NSDQ)
$5.16 USD
+0.32 (6.61%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $5.17 +0.01 (0.19%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth C Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, NeoGenomics, Inc. has a market cap of $625.22M, which represents its share price of $4.84 multiplied by its outstanding shares number of 129.18M. As a small-cap company, NEO's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NEO 5.16 +0.32(6.61%)
Will NEO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NEO
Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
NeoGenomics (NEO) Reports Break-Even Earnings for Q1
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
Other News for NEO
NeoGenomics (NEO) Stock Price Target Lowered by Morgan Stanley | NEO Stock News
NeoGenomics (NEO) Price Target Cut by Morgan Stanley amid Revenue Challenges
Peloton upgraded, Booking downgraded: Wall Street's top analyst calls
NeoGenomics price target lowered by $2 at Morgan Stanley, here's why
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with ...